<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01422915</url>
  </required_header>
  <id_info>
    <org_study_id>2010P002253</org_study_id>
    <nct_id>NCT01422915</nct_id>
  </id_info>
  <brief_title>Sorbent Therapy of the Cutaneous Porphyrias</brief_title>
  <acronym>EPP</acronym>
  <official_title>Sorbent Therapy of the Cutaneous Porphyrias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators demonstrated that cholestyramine is an effective binding agent in vitro for
      porphyrins. A few isolated case reports of treatment of individuals with a cutaneous
      porphyria suggest that cholestyramine and colestipol effectively remove porphyrins.
      Hypothesis: orally administered colestipol will effectively reduce sun sensitivity and lower
      erythrocyte porphyrin concentrations in subjects with erythropoietic protoporphyria (EPP).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Four adults with proven EPP volunteered as subjects for this study. First period: Subjects
      received 1 gm colestipol twice daily for ~45 days, then 2 gm twice daily for ~45 days. Labs
      included CBC; liver chemistries including cholesterol; serum iron, TIBC and ferritin;
      erythrocyte and plasma protoporphyrin concentrations; and completion of sun exposure
      questionnaire focused on cutaneous manifestations every 2-4 weeks. Second period: Subjects
      received colestipol tablets, 2 grams twice daily, completing the sun exposure questionnaire
      and protoporphyrin determinations ~monthly for 5-6 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">March 2012</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Photosensitivity, Assessed by Measuring the Number of Minutes of Sun Tolerance</measure>
    <time_frame>At 60 days of treatment</time_frame>
    <description>Minutes of sun tolerance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protoporphyrin Concentration in Blood</measure>
    <time_frame>Samples collected while on treatment (range 93-208 treatment days)</time_frame>
    <description>erythrocyte protoporphyrin concentration, ug/dl
plasma protoporphyrin concentration, ug/dl</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Erythropoietic Protoporphyria</condition>
  <arm_group>
    <arm_group_label>colestipol treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 grams morning and bedtime for 180 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colestipol</intervention_name>
    <description>2 grams morning and bedtime for 90 days.</description>
    <arm_group_label>colestipol treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult over age 21

          -  healthy

        Exclusion Criteria:

          -  Intercurrent illness

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2011</study_first_submitted>
  <study_first_submitted_qc>August 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2011</study_first_posted>
  <results_first_submitted>August 20, 2013</results_first_submitted>
  <results_first_submitted_qc>March 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Peter Tishler</investigator_full_name>
    <investigator_title>physician</investigator_title>
  </responsible_party>
  <keyword>Sorbent</keyword>
  <keyword>Resin</keyword>
  <keyword>EPP</keyword>
  <keyword>Cutaneous porphyria</keyword>
  <keyword>Adult</keyword>
  <keyword>over age 21</keyword>
  <keyword>without intercurrent illness</keyword>
  <keyword>not pregnant</keyword>
  <keyword>willing to participate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Porphyrias</mesh_term>
    <mesh_term>Porphyria, Erythropoietic</mesh_term>
    <mesh_term>Protoporphyria, Erythropoietic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colestipol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Dates: February and March 2011.Location types: suburbs of Massachusetts (3 subjects) and in New Jersey (1).</recruitment_details>
      <pre_assignment_details>All 4 subjects were enrolled in the study. Initially, baseline blood protoporphyrin concentrations and answers to sun sensitivity questionnaire were obtained.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Colestipol Treatment</title>
          <description>Colestipol 2 grams twice daily for 5-6 months. Completion of sun sensitivity questionnaire and blood protoporphyrin concentrations. were obtained monthly.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4">1 subject with abnormal liver chemistries removed during the first period.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Colestipol Therapy of Protoporphyria</title>
          <description>4 subjects were assigned, all between 18-65 years of age.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43" spread="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>For baseline in Period 1 and Period 2: ~monthly completion of sun sensitivity questionnaire; donate whole blood for RBC and plasma protoporphyrin</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Photosensitivity, Assessed by Measuring the Number of Minutes of Sun Tolerance</title>
        <description>Minutes of sun tolerance</description>
        <time_frame>At 60 days of treatment</time_frame>
        <population>All of the original 4 subjects had bona fide erythropoietic protoporphyria (EPP). One subject was removed during Perdiod 1. The data from the same 3 subjects who completed periods 1 and 2 were analyzed for the study results. Data collected was not tractable for statistical analysis given the range of results</population>
        <group_list>
          <group group_id="O1">
            <title>Colestipol Treatment</title>
            <description>gram morning and bedtime for 90 days; then
grams morning and bedtime for 90 days. Sun sensitivity questionnaires and blood protoporphyrin concns. were determined monthly.</description>
          </group>
        </group_list>
        <measure>
          <title>Photosensitivity, Assessed by Measuring the Number of Minutes of Sun Tolerance</title>
          <description>Minutes of sun tolerance</description>
          <population>All of the original 4 subjects had bona fide erythropoietic protoporphyria (EPP). One subject was removed during Perdiod 1. The data from the same 3 subjects who completed periods 1 and 2 were analyzed for the study results. Data collected was not tractable for statistical analysis given the range of results</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.8" spread="58.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Protoporphyrin Concentration in Blood</title>
        <description>erythrocyte protoporphyrin concentration, ug/dl
plasma protoporphyrin concentration, ug/dl</description>
        <time_frame>Samples collected while on treatment (range 93-208 treatment days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Colestipol Treatment</title>
            <description>Sun sensitivity and protoporphyrin levels</description>
          </group>
        </group_list>
        <measure>
          <title>Protoporphyrin Concentration in Blood</title>
          <description>erythrocyte protoporphyrin concentration, ug/dl
plasma protoporphyrin concentration, ug/dl</description>
          <units>ug/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Erythrocyte Protoporphyrin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1712" spread="455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma Protoporphyrin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>1st Period - Colestipol Optimal Dosage</title>
          <description>gram morning and bedtime for 90 days; then
grams morning and bedtime for 90 days. Sun sensitivity questionnaires and blood protoporphyrin concentrations were determined monthly.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal liver enzymes</sub_title>
                <description>Abnormal liver enzymes on one occasion.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>1 subject was removed during Period 1 because of abnormal liver chemistries.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Peter V. Tishler</name_or_title>
      <organization>BrighamHospital</organization>
      <phone>617-525-2123</phone>
      <email>repvt@channing.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

